Browsing by Author O'Brien, P

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2008The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials GroupDhillon, Haryana; Vardy, Janette; Au, Heather Jane; Booth, C.M.; Brundage, M.D.; Courneya, Kerry; Friedenreich, Christine; Gill, S; Meyer, Ralph.M.; O'Brien, P; Tu, Dongsheng; Psychology; Concord Clinical School: MedicineThe Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group, Current Oncology, vol.15, 6, 2008,pp 8-16
2008The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitrode Fazio, Anna; Murali, Rajmohan; Scolyer, Richard; Scurr, Lyndee; Barton, C; Davies, Michael; et, al; Gloss, B; Henderson, Michelle; O'Brien, P; Patterson, K I; Saunders, D; Scurry, J; Smith, Alison N.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: Pathology; Central Clinical School: Pathology; Western Clinical School: Medicine (Westmead)The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro, British Journal of Cancer, vol.98,(6),2008,pp 1085-1093
2011Monoclonal Antibody Targeting MUC1 and Increasing Sensitivity to Docetaxel as a Novel Strategy in Treating Human Epithelial Ovarian CancerMadigan, Michele; Chen, Hongmin; Hao, Jingli; Li, Yong; Liu, FengHua; O'Brien, P; Patterson, K I; Perkins, Alan C.; Pourgholami, Mohammad H; Power, Carl A.; Wang, Li; Central Clinical School: Clinical Ophthal & Eye HealthMonoclonal Antibody Targeting MUC1 and Increasing Sensitivity to Docetaxel as a Novel Strategy in Treating Human Epithelial Ovarian Cancer, Cancer Letters, vol.300, 2, 2011,pp 122-133